Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR

doi 10.1021/acsmedchemlett.6b00005.s001

Full Text

Abstract

Available in

Date

Unknown

Authors

Unknown

Publisher

American Chemical Society (ACS)

Related search

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate

English

The Brain-Penetrant Clinical ATM Inhibitor AZD1390 Radiosensitizes and Improves Survival of Preclinical Brain Tumor Models

Science advances

Multidisciplinary

English

A Brain-Penetrant MET Inhibitor Achieves Responses in Glioblastoma

Cancer Discovery

English

A Brain Penetrant Mutant IDH1 Inhibitor Provides in Vivo Survival Benefit

Scientific Reports

Multidisciplinary

Breton

Preclinical Evaluation of a Novel Triple-Acting PIM/PI3K/mTOR Inhibitor, IBL-302, in Breast Cancer

Cancer Research

Molecular Biology

English

The Dual PI3K/mTOR Inhibitor, NVP-BEZ235, Is Efficacious Against Follicular Lymphoma

Cancer Research

English

GDC: Group Discovery Using Co-Location Traces

English

Pre-Clinical Activity of Targeting the PI3K/Akt/mTOR Pathway in Burkitt Lymphoma

English

NVP-BEZ235, a Novel Dual PI3K/mTOR Inhibitor, Enhances the Radiosensitivity of Human Glioma Stem Cells in Vitro

Acta Pharmacologica Sinica

English